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Abstract
Background: The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility randomised
controlled trial examining the effect on lung cancer diagnosis of lowering the threshold for referral for urgent chest
x-ray for smokers and recent ex-smokers, aged over 60 years with new chest symptoms. The qualitative component
aimed to explore the feasibility of individually randomising patients to an urgent chest x-ray or not and to
investigate any barriers to patient recruitment and participation. We integrated this within the feasibility trial to
inform the design of any future definitive trial, particularly in view of the lack of research exploring symptomatic
patients’ experiences of participating in diagnostic trials for possible/suspected lung cancer. Although previous
studies contributed valuable information concerning screening for lung cancer and patient participation in trials,
this paper is the first to explore issues relating to this specific patient group.
Methods: Qualitative interviews were conducted with 21 patients, comprising 9 who had been randomised to
receive an immediate chest x-ray, 10 who were randomised to receive the standard treatment according to the
National Institute for Health and Care Excellence guidelines, and 2 who chose not to participate in the trial.
Interviews were analysed using a framework approach.
Results: The findings of this analysis showed that altruism, personal benefit and the reassurance of not having lung
cancer were important factors in patient participation. However, patients largely believed that being in the
intervention arm was more beneficial, highlighting a lack of understanding of clinical equipoise. Disincentives to
participation in the trial included the stigmatisation of patients who smoked (given the inclusion criteria). Although
the majority of patients reported that they were happy with the trial design, there was evidence of poor
understanding. Last, for several patients, placing trust in health professionals was preferred to understanding the
trial processes.
Conclusions: The integration of a qualitative study focusing on participant experience as a secondary outcome of a
feasibility trial enabled exploration of patient response to participation and recruitment. The study demonstrated
that although it is feasible to recruit patients to the ELCID trial, more work needs to be done to ensure an
understanding of study principles and also of smoking stigmatisation.
Trial registration: ClinicalTrials.gov, NCT01344005. Registered on 27 April 2011.
Keywords: Feasibility studies, Lung neoplasms, Patient preference, Primary healthcare, Qualitative research, Quality
of life, Random allocation, Referral and consultation, Smoking, X-rays
* Correspondence: prouth@cardiff.ac.uk
†Richard D. Neal and Annmarie Nelson contributed equally to this work.
1Marie Curie Palliative Care Research Centre, School of Medicine, Cardiff
University, Cardiff, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Prout et al. Trials  (2018) 19:419 
https://doi.org/10.1186/s13063-018-2803-4
Background
Lung cancer is the most common cause of cancer death in
the United Kingdom, accounting for more than one in five
cancer deaths. However, survival rates have not shown a
great improvement in the last 40 years [1]. Furthermore,
lung cancer survival rates in the United Kingdom and
Ireland have been shown to be lower than the European
average [2]. To address this inequity, several initiatives
have been set up, such as the National Awareness and
Early Diagnosis Initiative (NAEDI) [3] and the Together
for Health Cancer Delivery Plan for the NHS for 2016 [4].
Options for earlier-stage diagnosis include the develop-
ment of predictive biomarkers, getting general practitioners
(GPs) to investigate symptoms more quickly (as in this
trial), allowing GPs access to low-dose computed tomog-
raphy [5], population screening programmes [6], and
targeted public awareness campaigns to encourage earlier
presentation of symptoms [7, 8].
The ELCID trial
The ELCID (Early Lung Cancer Investigation and Diag-
nosis) feasibility clinical trial [9] is an NAEDI-funded
trial examining the value of lowering the threshold for
ordering a chest x-ray for suspected lung cancer symp-
toms in the primary care setting. Specific outcomes
included evaluating trial design, materials and inter-
vention and the training and recruitment of practices,
including the recruitment and randomisation of pa-
tients (Fig. 1). The control group was investigated in
accordance with contemporary National Institute for
Health and Care Excellence (NICE) referral guidance
(at the time), whereby they would undergo urgent re-
ferral with one of a number of chest symptoms present
for more than 3 weeks. The trial intervention, which
we have termed ‘Extra-Nice’, meant randomised pa-
tients would receive an urgent chest x-ray if they pre-
sented with one of a number of chest symptoms of any
duration, smoked or were ex-smokers, and were over
60 years of age. Patients deemed eligible to participate in
the trial included those over 60 years old who were either
smokers or ex-smokers with a smoking history of 10 or
more pack-years and who presented at a general practice
with a new or altered cough of any duration or increased
breathlessness or wheezing (whether or not associated
with purulent sputum) [10].
This feasibility study was set up to inform the design of a
large UK-wide clinical trial [9] of lowering the threshold for
investigating patients presenting with symptoms of possible
lung cancer. By lowering the threshold, it is hypothesised
that clinical outcomes in lung cancer, as well as the
cost-effectiveness of lung cancer diagnosis, may be im-
proved. The study involved health economics, quality of life,
and qualitative and quantitative methods in order to fully
assess feasibility. This paper reports the qualitative findings.
Fig. 1 Recruitment and randomisation of patients
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The ELCID qualitative study
Within the ELCID trial, an integrated qualitative study
was carried out with the aim of exploring the feasibility
of individually randomising patients to an urgent chest
x-ray or not and to investigate any barriers to patient
recruitment and participation. This integrated qualitative
study is timely, considering the high mortality rates of
lung cancer and the lack of research exploring symptom-
atic patients’ experiences of participating in trials for the
possible diagnosis of lung cancer.
Our paper is one of only five which have explored pa-
tient experiences of lung cancer investigation and referral
[11–13]. Banks and colleagues [12] investigated patient
preferences for diagnostic testing for cancers including
lung cancers using vignettes with primary care attendees.
They found that participants expressed a preference for
diagnostic testing at all risk levels and at levels below
those stipulated by UK guidelines. Birt and colleagues [11]
explored symptom appraisal and help-seeking decisions
amongst patients with symptoms suggestive of lung
cancer using in-depth qualitative interviews. They used
this information to guide lung cancer awareness cam-
paigns highlighting the importance of social networking
and GP advice and monitoring. Banks and colleagues [13]
highlighted minimal patient involvement in and under-
standing of referral decisions for investigation of lung and
colorectal cancers. The qualitative interviews also brought
to light GPs keeping dialogue non-specific and tending
not to mention the possibility of cancer. Rankin and col-
leagues [14] used qualitative interviews and focus groups
to explore the perspective of GPs and of their patients
who had been placed on a lung cancer diagnostic pathway.
Using the Model of Pathways to Treatment as a frame-
work for analysis, they found that respondents felt that
significant improvements should be made to health sys-
tems to improve experiences relating to diagnostic and
pre-treatment intervals.
These studies highlight important information relating
to symptom appraisal of lung cancer and diagnostic
pathways to treatment. However, our study fills a need
to explore patient experiences of specifically participat-
ing in a randomised controlled trial (RCT) relating to a
potential lung cancer diagnosis. Because RCTs are con-
sidered of great importance in carrying out rigorous
research [15–17], an insight into patient experiences of
participating in an RCT to diagnose a possible lung cancer
is of great importance.
The benefits of embedded qualitative research
Recent integrated studies have generated valuable insight,
such as patient preferences in a non-inferiority trial [18];
patient evaluations of trial principles, processes and prac-
tices in a non-placebo clinical trial for patients with
advanced lung cancer [19]; issues of clinical equipoise and
patient (mis)understandings in feasibility trials that ex-
perienced recruitment difficulties [20–24]; patient ex-
pectations of cancer diagnostics [12]; and participants’
understanding of complex trial processes in a stratified
trial of personalised therapies [25]. Additionally, partici-
pant interview data highlighting trial processes in need
of improvement may be used in real time to allow ne-
cessary protocol amendments in order to improve re-
cruitment and retention of participants [26]. The ELCID
qualitative study is reported in line with the guidelines set
out in Consolidated Criteria for Reporting Qualitative
Research (COREQ) [27].
The aim of this paper
This paper reports the findings of the qualitative study
that relate to participant understanding and acceptability
of the trial and processes, such as recruitment and ran-
domisation. By considering patient experience as a sec-
ondary outcome of the feasibility study, recommendations
can then be made to inform the design of the ELCID
phase 3 trial.
Methods
Study design
This was a multicentre, qualitative study which was
embedded within a trial.
Recruitment
The eligibility criteria for patients to be recruited into the
main trial were the same for the qualitative interview study:
patients over 60 years old who were either smokers or
ex-smokers with 10 or more pack-years of smoking history
and who presented at a general practice with a new or
altered cough of any duration or increased breathlessness
or wheezing (whether or not associated with purulent spu-
tum). Therefore, all patients approached to take part in the
ELCID trial (whether they chose to participate or not) were
eligible to take part in the qualitative interview study, too.
In addition to the eligibility criteria for the trial, however,
patients were also required to be able and willing to discuss
issues relating to their diagnosis, treatment, and quality of
life and to be able to understand questions and speak
English to the extent needed to participate in the interview.
Patients who experienced any problems that affected their
communication or comprehension were not included in
the study. None of the patients, whether they participated
in the trial or the interview study, were compensated for
taking part. Patient characteristics are set out in Table 1.
Patients were recruited into the study during their
appointments with their GPs and at that time also indi-
cated if they wanted to take part in the interview study,
too (Fig. 2). Patients who declined consent for the trial
were also asked if they would like to participate in the
interview study, too. Sixty-four patients’ contact details
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were faxed to the qualitative researcher, and 22 of these
patients were ultimately interviewed. The researcher tel-
ephoned the patients to determine an interview date. Pa-
tients were given at least 24 hours to decide whether to
participate in the study. Consent was taken at the time
and place of interview.
Sampling and data collection
Thirty-four GP practice sites were open to recruitment.
Purposive sampling was used according to the eligibility
criteria set out above. Qualitative interviewing data were
collected from 21 patients, 9 of whom had been rando-
mised to receive an earlier chest x-ray, 10 of whom had
been randomised to receive the standard treatment ac-
cording to NICE guidelines, and 2 who chose not to
participate in the trial. Recruitment for the interviews
ceased when data saturation was reached [28]. However,
the researchers managed to recruit only two patients for
interview who declined trial participation. Although nine
initially agreed to be interviewed, one patient changed
their mind and seven were not contactable. Data satur-
ation for this group was therefore not achieved.
The qualitative interviews
The trial and the interviews were carried out simultan-
eously. The interviews, which lasted between 30 minutes
and 1 hour, were carried out by a female researcher with a
good knowledge of the healthcare system and experienced
in qualitative interviewing. Although the researcher had a
clinical background, she assumed the researcher role for
the interviews. She did not hold any strong views about
smoking and healthcare and remained neutral on issues
Table 1 Participant characteristics of those interviewed for the
ELCID Qualitative Study
(ID no.) Group Sex Area recruited
1 Control Female South East Wales
2 Intervention Female South East Wales
3 Control Female South East Wales
4 Control Female South East Wales
5 Intervention Female South East Wales
6 Intervention Female South East Wales
7 Intervention Male South East Wales
8 Intervention Male South East Wales
9 Intervention Female South East Wales
10 Intervention Male South East Wales
11 Intervention Female South East Wales
12 Control Female South East Wales
13 Control Male South East Wales
14 Control Male South East Wales
15 Intervention Female South East Wales
16 Control Male South East Wales
17 Control Female South East Wales
18 Control Female South East Wales
19 Control Male South East Wales
20 Declined trial Female North Wales
21 Declined trial Female North Wales
22 Intervention (withdrawn) Female South East Wales
Fig. 2 Recruitment of patients for the qualitative interview study
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that were discussed with the patient. She contacted the
patients before visiting them in their homes and answered
any questions that the patients asked.
Patients were given the choice of being interviewed either
at their home or at their GP’s general practice. However, the
patient ‘decliners’ were offered a telephone interview if they
lived a long distance from the researcher’s place of work.
Three patients were accompanied in the interview by
their spouse or partner, who was not additionally con-
sented. For the most part, they stayed silent apart from
their brief input, which was (1) to point out how nice a
hospital was, (2) to agree with the patient that he did not
need to wait long for an appointment, and (3) to clarify
what the patient had said about the importance of the
study. This input was not analysed and used for the paper.
The interview guide reflected the aim of the study: to
explore the feasibility of individually randomising pa-
tients to an urgent chest x-ray or not and to investigate
any barriers to patient recruitment and participation.
Topics included the following:
 Feelings about being approached to participate in a
trial concerning lung disease
 Reasons for taking part in the trial (or not)
 Experiences of taking part in the trial (if agreed to
take part)
 Understanding of the trial design
The interview guide remained unchanged throughout
data collection because no new topics were highlighted
during the first few interviews.
Data analysis
Once all the interviews had been completed, they were
uploaded via digital media for transcription using a stand-
ard operating procedure to ensure participant confidential-
ity. The anonymised transcripts were transcribed verbatim
and uploaded to NVivo 10 software [29], and relevant ex-
tracts were isolated and coded. Data analysis was conducted
via the Framework Analysis approach [30], which is suited
to applied healthcare research situations where the aim of
the study is to inform future practice, based on existing
practice, rather than theoretical development. The analysis
techniques include familiarisation (where the researcher be-
comes immersed in the data), developing a theoretical
framework (where a hierarchical thematic framework is de-
veloped to classify and organise data into key themes, con-
cepts, and categories), indexing (where the framework is
applied to the original data transcripts and coded accord-
ingly), charting (where each theme is charted using a table
or matrix using summaries of the data), and mapping and
interpretation (where the charts and data are examined for
patterns and connections). Co-coding was carried out by
the main qualitative researcher and a second qualitative
researcher who worked in the same department. The sec-
ond researcher carried out 10% of the interviews to ensure
validity of the analysis and to verify interpretation. A the-
matic hierarchy was then produced. Any disagreements
were resolved through discussion. Although data analysis
commenced while the trial was ongoing, findings were too
early to result in changes to the conduct of the trial.
Results
These results reflect the aim of the study and the topics
set out in the interview guide. They elucidate the rea-
sons why patients decided to take part in the trial, their
comprehension relating to trial design and processes,
and their experiences of taking part in the trial and
receiving a chest x-ray.
Reasons for taking part in the trial
The majority of interview participants were happy to be
approached for the study. Reported motivations for
participating in the trial were mostly a combination of
helping others, future generations, and themselves, with
some patients stating that their family influenced their
decision to participate.
Altruistic reasons for taking part
Several patients stated that they agreed to take part in
the research in order to help their families. One patient
said that it made her feel better to help her grandchildren
and her husband;
‘Well why I, I um done it [...] like I said is because of
my grandchildren and my husband as well ’cos he had
it, and I thought it was good thing for me to do like
[...] and I felt I felt better because I done these things
you know’. (Patient id2 female intervention arm)
Respondents also made reference to participating for
those whom they had lost. One respondent referenced
her involvement as taking place in memory of a friend
who had died of cancer:
‘My friend had died from ovarian cancer right a few
years before. […] I thought that [the trial] was something
I was doing for her in a way if you know what I mean’.
(Patient id3 female control arm)
Some patients also said that they explicitly wanted to
help further medical research in the field of lung diseases:
‘If it helps anything to do with you know medical
research [...], yeah, I don’t mind helping, ay’.
(Patient id13 male control arm)
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Others expressed a moral duty to contribute in repay-
ment for previous healthcare:
‘It would be nice to give something back’.
(Patient id14 Male control arm)
Personal gain
Patients made reference to taking part in the research in
order to help themselves. One patient stated that although
the main reason he participated was to help other people,
he also thought that he would benefit from a chest x-ray
by having a chest diagnosis:
‘It’s a good cause try to help people I help myself like
right […] they can find out what’s wrong with my chest,
and I’m helping other people; that’s the reason why I’m
doing it really’. (Patient id8 male intervention arm).
Another patient stated that it was important to have
tests in order to diagnose a problem early:
‘To catch it early, you got a chance of living that much
longer’.
(Patient id15 female intervention arm)
Concerns about taking part in the trial
A number of concerns about joining the trial were raised
by participants and non-consenters. One patient pointed
out that she did not want to take part in the trial but felt
obliged to do so because the letter of invitation had orig-
inated from her GP (patient id15 female intervention
arm). Her decision to participate was further based on
the assurance that she would not be inconvenienced by
extra travel. Another expressed anxiety about a poor
medical outcome seemingly influenced by media report-
ing of a previous trial, and another patient was worried
that she may have lung cancer:
‘It [a large placebo trial] had quite a devastating effect
on some of them [young people] [...]; that concerned me’.
(Patient id6 female intervention arm)
‘I was afraid I was very apprehensive about it because
I had a chest infection and I thought, “Oh God,
perhaps they think I’m a candidate for lung cancer or
something”’.
(Patient id3 female control arm)
One participant thought that she had been invited to
take part in the trial because of her smoking status or
history of smoking and the fact that she may have lung
cancer, highlighting a smoking stigma:
‘[I] felt a bit app, apprehensive first of all because I’m
an ex-smoker [...], and I thought, “God, why have they
picked on me?”’
(Patient id3 female control arm)
The two participants who declined the trial gave differ-
ent reasons for doing so, although both made connec-
tions to their own or others’ smoking behaviours. One
trial decliner had previously been approached by
health professionals multiple times about quitting
smoking and assumed that she was again being
approached:
‘I thought it was about the stop smoking campaign,
yeah, because, er, every time I’ve been to see anybody
at the hospital or anything, everybody always says to
me, “Would you like to stop smoking?”’
(Declined trial id20 Female)
The other trial decliner stated that she was nervous
anyway about being approached for the trial because her
father, who had been a heavy smoker, had very recently
died of lung cancer:
‘I just lost me dad in November […], but he was a
heavy smoker […], never went to the doctors’.
(Declined trial id21 Female).
Understanding and acceptance of trial design
A few patients showed some understanding of the trial.
For example, one patient clarified that she understood
the concept that not all patients would receive a chest
x-ray:
‘It’s random; only so many people can go [...], so it
wouldn’t have bothered me at all [if I had not received
an X-ray]’.
(Patient id5 female intervention arm)
However, many patients were confused about the
process of randomisation, with some believing that the
process of being assigned to an arm of the trial was de-
cided by the doctor in view of their past medical history
or their smoking status:
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‘What I thought was information was fed into this
computer that I smoked [...], and maybe that’s how
they come to the decision that the people had it [the
chest x-ray] or not’.
(Patient id6 female intervention arm)
Another believed that he had not been assigned a
chest x-ray, because the doctors had taken his medical
history into account inasmuch as he had previously been
for chest x-rays:
‘I haven’t got to go for the x-ray, so obviously they must
have seen something in my immediate past that doesn’t,
um, merit me going for an x-ray,’cos I’ve been for x-rays’.
(Patient id16 male control arm)
Understanding and acceptance of the control/standard
care arm
It was apparent that several of the standard care patients
had not adequately understood management allocation
prior to agreeing to participate in the trial.
Misconceptions relating to the control/standard care arm
One standard care patient pointed out that he could not
grasp an understanding of the purpose of the control arm:
‘It’s just, I do not understand it [...] sounds pointless.
Very pointless, actually.
(Patient id19 male control arm)
Furthermore, many standard care patients believed
that they were to have a chest x-ray well into the trial
period. One patient stated that she had only entered
onto the trial for the purpose of having a chest x-ray:
‘Yes, because that was the whole idea in the beginning of
deciding […] whether to go for it, I thought.[…] Other
than that, to me, it [the trial] would be a bit pointless’.
(Patient id12 female control arm)
Other standard care patients similarly described the
benefits that they thought they would access by having
the chest x-ray in terms of peace of mind and timely
intervention if required:
‘I just thought, oh, erm, lung disease research, it would
be good. Peace of mind to know that my lungs were ok,
[...] so I assumed that I would be x-rayed’. (Patient
id17 female control arm)
‘It could have been caught it in time, then, and they
possibly [could] do something about it’.
(Patient id13 male control arm)
Another expected to have medical tests and could not
understand why their health was not being investigated
and all that they were doing was ‘filling in forms’:
‘[I expected] tests of some sort. [...] But it’s just [...]
filling in a couple of forms, and that’s it.
(Patient id19 male control arm).
(non)-acceptance of control/standard care arm
Some patients felt that they would not have the best
treatment if they were randomised to standard care, in-
dicating a lack of understanding of trial equipoise. This
was of particular concern for patients who believed that
they needed a chest x-ray because of their symptoms.
One patient even believed that being on the trial might
mean a chest x-ray would not be taken even if clinically
indicated during their routine care:
‘I mean, I could be a really bad case, but because I
wasn’t chosen’.
(Patient id17female control arm)
Two patients on the intervention arm also indicated their
hypothetical non-acceptance of the control arm, explaining
that they would have possibly returned to see their GP to
request an x-ray if they had been placed on the standard
arm of the trial and were continuing to feel ill:
‘Maybe I would have gone back and said, look, I need
to have one if that’s how they do it’. (Patient id10 male
intervention arm).
However, although several of the standard care pa-
tients voiced an explicit preference for a chest x-ray and
were disappointed not to receive one, many others ac-
cepted their allocation to the standard care or were in-
different to the issue:
‘I’m indifferent on it, you know, either way I wouldn’t have
minded [...] whether I had the x-ray or whether I don’t’.
(Patient id13 male control arm)
Only one patient (standard care) stated a preference
for the control arm, explaining that she would not have
wanted a chest x-ray ‘because [of] fear’ of a potential
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cancer diagnosis (Patient id3 female control). She con-
tinued that she would prefer not to know “let’s just say
ignorance is bliss” (Patient id3 female control). Even so,
she would have accepted randomisation to receive a
chest x-ray and continued on the trial.
Patient experiences of the intervention arm (chest x-ray)
There did not appear to be any misunderstandings relat-
ing to the intervention or chest x-ray arm of the trial
and those who had received their x-rays spoke positively
about the process and outcome:
‘Brilliant. That’s all I can say. [...] You know, it could
have saved my life, well you know, lucky enough it
didn’t have to, but it could have’.
(Patient id11 female intervention arm)
Some patients also described how the results of the
x-ray affected their smoking behaviour. One patient said
that the opportunity of having a chest x-ray inspired him
to improve his personal health, because he could quit
smoking with the knowledge that he did not have cancer:
‘It put my mind to rest to think, right, you’d better
start getting yourself together now your chest is ok’.
(Patient id10 Male intervention arm)
For another patient, however, it seems that a clear re-
sult of the chest x-ray would help to validate his smok-
ing habit. He explained how he had smoked for 54 years
and felt that smoking had not yet affected him, and a
clear result would only confirm this:
‘Everybody is telling me to give up smoking, but I’ve
smoked about 54 years now. […] If this one comes up
and it just confirms the first one [...], carry on smoking’.
(Patient id7 Male intervention arm)
Receiving results
The patients who received a chest x-ray seemed to have
no particular difficulties with the process of having the
chest x-ray, stating that receiving the results of their
chest x-ray was fast and efficient. One patient, however,
received results that required further investigation,
which understandably caused her significant anxiety:
‘Terrible. It’s the waiting is the worst. I don’t think they
get you in quick enough’.
(Patient id11 female intervention arm)
Transport to hospital
Some patients stressed how easy it was to get to the hos-
pital because certain surgeries provided taxi transporta-
tion, whereas others used public transport or otherwise
with no issue:
‘When they [the practice] said [hospital name 1], I
said could I go to [hospital name 2], [...] and they said
why is that? I said because parking up the [hospital
name 1] is horrendous. Oh, don’t worry about that, she
said, we’ll get you a taxi.
(Patient id11female intervention arm)
“I went up on my own; I wasn’t afraid.” (Patient id2
female intervention arm).
However, a small minority of patients found the
process of getting a chest x-ray difficult. One patient
said that she had to pay for the parking costs and that
using public transport would be too problematic (Patient
id9 female intervention arm), whereas another patient
stated that it would be too difficult to walk to the hos-
pital in view of her ill health:
‘The only thing is paying for the car to park. A
nuisance. [...] The stupid little car park […], you
couldn’t walk there. If you had to get a bus, it would
be a major operation’.
(Patient id10 male intervention arm)
Patient evaluation of trial processes and documentation
Data collection processes
Some patients appeared to have a vague understanding
of the course of the trial and what this entailed. How-
ever, several patients were unaware that they would re-
ceive a follow-up questionnaire after a few months, and
one patient commented that she had not expected to be
interviewed:
‘I didn’t realise at the time that somebody was going
to come, like yourself ’.
(Patient id6 female intervention arm)
Views on trial documentation and materials
In spite of the general lack of understanding of the trial
processes, patients were generally positive about the trial
documentation, with almost all of them saying that it
was clear, informative and precise. Patients also seemed
happy with the process of giving consent because they
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were not ‘pressured or pushed into it’ (Patient id9 female
intervention arm) and had the option to withdraw from
the study at any time:
‘I hope I’ll see it through, but, um, as I say, if I’m
allowed to say that’s it, I don’t want anymore, that’s
good enough for me’.
(Patient id14 male control arm)
In general, many patients preferred to receive informa-
tion verbally. One stated that this is because she could
ask questions if there was anything that she did not
understand, whereas another thought she would remem-
ber it better if it was explained to her:
‘I think it’s clearer if a person tells you because, um,
when somebody’s talking to you, if you don’t
understand something, you can ask them, [...] you
know, whereas when you’re reading it [...], there’s no
one to ask.’
(Patient id11 female intervention arm)
Some preferred to receive information both verbally
and in written format in order to compound knowledge,
whereas others stated that they preferred receiving writ-
ten information because it was more information and
you could take it home to read. Some had no preference.
However, some patients reported problems with the
documentation, namely data collection questionnaires.
For example, one patient had difficulties regarding the
clarity of a particular question asking whether she was
anxious or depressed:
‘There was one particular [question] [...]. It was, um,
do you think you have or do you think you’re anxious
or depressed? [...] I said to the lady, you know, how do
I answer this, because I am anxious but I’m not
depressed?’
(Patient id11 female intervention arm)
Two patients pointed out that they thought that the
patient questionnaire was intrusive:
‘I thought maybe one or two could have been a bit
intrusive [...], but not to me, you know, I don’t mind
[…]. Other people may think you know some of the
questionnaire was a bit intrusive like [...], but, er, as
far as I was concerned, it was, you know,
straightforward’.
(Patient id13 male control arm)
Preference for limited information and trusting in health
professionals
Several patients preferred to take a more passive role in
the trial, explaining how they did not feel the need to
understand the inner workings of the trial because they
felt able to trust their doctors and other practice staff to
do right by them:
‘I felt that you would understand everything, whoever
did the trials [...], and really there was no need for me
to [...]really understand fully’. (Patient id12 female
control arm)
Likewise, another patient said that he would accept
whichever arm of the trial to which he was randomised,
owing to his trust in the research team:
‘You people [...] are running the show, you know,
captain of the ship, so that’s it, you obey’.
(Patient id7 male intervention arm)
Discussion
We carried out 21 qualitative interviews as an integral
component of the ELCID feasibility clinical trial in order
to explore patient response to participation and recruit-
ment to a trial associated with lung cancer diagnosis and
a chest x-ray referral. The results showed that altruism,
personal benefit and the reassurance of not having lung
cancer were important factors in patient participation.
However, patients largely believed that being in the
intervention arm was more beneficial, highlighting a lack
of understanding of clinical equipoise. Disincentives to
participation in the trial included the stigmatisation of
patients who smoked, owing to the inclusion criteria.
Although the majority of patients reported that they
were happy with the trial design, there was evidence of
poor understanding. Last, for several patients, placing trust
in health professionals was preferred to understanding the
trial processes.
Reasons for taking part in the trial
Our study highlighted that altruism and perceived med-
ical benefit, including reassurance of not having lung
cancer, were motivations to take part in this trial. Others
have similarly identified medical benefit to be a primary
motivation for taking part in trials, with participants
joining trials in the hope of accessing treatments which
might help them [18, 19, 31]. In this study, this attitude
related to a belief amongst many participants that an
early chest x-ray is important for earlier diagnosis of
cancer. This may mirror a more widespread public atti-
tude towards tests, as suggested in the study by Banks
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and colleagues [12] noted above, which found a clear
preference for testing in spite of relatively low risk levels.
What this also demonstrates, however, is a lack of un-
derstanding or acceptance of trial equipoise amongst
many participants and possible diagnostic misconcep-
tion, with some patients apparently joining the study be-
cause of a perceived clinical need and assumed benefit
from receiving the intervention. Previous research has
similarly highlighted patient difficulties in understanding
or accepting clinical equipoise, for reasons such as pa-
tient/public beliefs about particular treatment options
(as indicated above) [22, 23, 32], perceived clinical prefer-
ences for particular treatment arms [19, 21, 23, 24, 33],
and an orientation towards trusting the experts and their
expertise when making treatment decisions (as opposed to
accepting clinical uncertainty and the related need for an
RCT) [19–21, 23, 24, 34]. Indeed, Mills and colleagues
[21] pointed out that clinical equipoise or the consensus
by experts that there are no merits to either treatment
being tested had an effect on participation in their trial of
treatments for prostate cancer. They found that those pa-
tients who did not accept the ‘equipoise’ in the trial were
less likely to participate.
Concerns over taking part in the trial
Many participant misunderstandings of the nature of the
ELCID trial were closely related to attitudes and beliefs
regarding the study. Two patients who had agreed to be
interviewed for the ELCID interview study chose not to
participate in the trial because of a perceived smoking
stigma. It is therefore possible that there were other po-
tential participants who chose not to take part in the
trial because of the associated smoking stigma and a
belief that the trial involved a smoking cessation inter-
vention. This reinforces findings of the das Nair and col-
leagues study [35], which highlighted stigmatisation
related to smoking as a barrier to possible recruitment
to a lung cancer screening trial.
A small number of patients reported cancer anxiety
upon receiving the initial letter of invitation to partici-
pate in ELCID. Banks and colleagues [13] also noted that
anxiety was raised only when patients had been referred
for a chest x-ray and there was a lack of information
given to the patient.
Understanding and acceptance of trial design
There have been no studies exploring participant under-
standing of diagnostic lung cancer trials. Although there
were some patients who expressed an understanding of
randomisation and the trial processes, the majority did not,
with a number of patients perceiving that their allocation
was based on clinical assessment, as also noted in other
studies [23]. Our study shows that many patients’ expecta-
tions are misinformed or confused. This was despite
significant patient and public involvement input into the
design of materials and ethics committee processes. The
general literature concerning patient understanding of
RCTs provides further evidence of participants’ poor un-
derstanding of trials and key principles such as randomisa-
tion and equipoise [22, 23, 31, 36–38]. In a recent
systematic review and meta-analysis of the quality of in-
formed consent of clinical trials, Tam and colleagues [38]
found some aspects of the trial were not understood by
participants. Whilst there was understanding of the bene-
fits of the voluntary nature of the study, the concepts of
randomisation and placebo were not understood. They
point out that this lack of understanding had not changed
over 30 years.
Patient evaluation of trial processes and documentation
Our study revealed the extensive influence of healthcare
professionals in information-giving and decision-making.
This could partly be the reason for participants’ not un-
derstanding the information, because they may be rely-
ing on health professionals rather than themselves to
take more notice of the content of the trial. Banks and
colleagues [13] also noted that patients who had been
referred for a chest x-ray expected the GP rather than
themselves to make this decision to have this test.
Locock and Smith [31] carried out qualitative inter-
views with participants who had previously taken part in
clinical trials for a range of different conditions. They,
too, found that trust in the medical and nursing staff
was a common theme, with some participants stating
that they had not really read the information sheet but
preferred to put their trust in discussing the trial with
the clinical team instead. Alternatively, Doyal [39]
pointed out that some patients have problems with un-
derstanding clinical information and therefore do not
wish to participate in making decisions.
Strengths and limitations of the study
Our study is the first to explore the experiences of
symptomatic patients who are participating in trials for
possible lung cancer. Although previous studies contrib-
uted valuable information concerning screening for lung
cancer and patient participation in trials, this paper ex-
plored issues relating to this specific patient group. It is
one of only four which have explored patient experi-
ences of lung cancer investigation and referral [11–13].
A further strength of this study is that not only patients
from the intervention and control arms of the trial but
also those who refused to take part in the trial were
interviewed.
A limitation of the study is that the two patients who
declined to take part in the main trial highlighted im-
portant information regarding smoking stigma. A larger
sample within this decliners group could have generated
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more information regarding why patients refused to partici-
pate in the ELCID clinical trial. A further limitation could
be gender and geographical biases. There were double the
amount of females who participated in the interview study
(females, n = 14 [1 withdrawn]; males, n = 7). Also, all pa-
tients who participated in the trial and the interview study
were from southeastern Wales, and none were from North
Wales and Yorkshire. The two patients who declined the
trial were from North Wales.
Conclusions
The integration of a qualitative component focused on
participant experience as a secondary outcome of a
feasibility trial has enabled exploration of patient re-
sponse to participation and recruitment. This has
demonstrated that although it is feasible to recruit pa-
tients to the ELCID trial, more work needs to be done
to ensure an understanding of study principles and
also of smoking stigmatisation. Recommendations for
the next phase of the ELCID diagnostic trial include
the following:
 To motivate patients to take part in future lung
cancer diagnostic trials, importance needs to be
placed on highlighting the possibility of helping
others and advancing medical science.
 Patients should be supported to take the necessary
time to ensure understanding of patient information
sheets before signing consent, especially with regard
to clinical equipoise and that they will not
necessarily benefit from participation.
 Patients should be assured that the aim of the study
is not to stop smoking, because it seems that this
may limit recruitment owing to smoking
stigmatisation.
 Consideration should be given to a shared decision-
making approach for those patients who are less
motivated to make decisions on their own behalf.
 Patients should be reassured that participation in the
trial should cause the patient the least amount of
inconvenience, especially in terms of travel
necessities.
These recommendations should be considered for fu-
ture trials concerning lung diagnostics. They can also be
used when considering any trial and the need to support
patients to understand the study in which they are con-
senting to participate.
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